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Abstract
The microbial adaptive immune system CRISPR mediates defense against foreign genetic 
elements through two classes of RNA-guided nuclease effectors. Class 1 effectors utilize multi-
protein complexes, whereas Class 2 effectors rely on single-component effector proteins such as 
the well-characterized Cas9. Here we report characterization of Cpf1, a putative Class 2 CRISPR 
effector. We demonstrate that Cpf1 mediates robust DNA interference with features distinct from 
Cas9. Cpf1 is a single RNA-guided endonuclease lacking tracrRNA, and it utilizes a T-rich 
protospacer adjacent motif. Moreover, Cpf1 cleaves DNA via a staggered DNA double stranded 
break. Out of 16 Cpf1-family proteins, we identified two candidate enzymes, from 
Acidominococcus and Lachnospiraceae, with efficient genome editing activity in human cells. 
Identifying this mechanism of interference broadens our understanding of CRISPR-Cas systems 
and advances their genome editing applications.
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Almost all archaea and many bacteria achieve adaptive immunity through a diverse set of 
CRISPR-Cas (Clustered Regularly-Interspaced Short Palindromic Repeats and CRISPR-
ASsociated proteins) systems, each of which consists of a combination of Cas effector 
proteins and CRISPR RNAs (crRNAs) (Makarova et al., 2011; Makarova et al., 2015). The 
defense activity of the CRISPR-Cas systems includes three stages: (i) adaptation, when a 
complex of Cas proteins excises a segment of the target DNA (known as a protospacer) and 
inserts it into the CRISPR array (where this sequence becomes a spacer); (ii) expression and 
processing of the precursor CRISPR (pre-cr) RNA resulting in the formation of mature 
crRNAs; and (iii) interference, when the effector module – either another Cas protein 
complex or a single large protein – is guided by a crRNA to recognize and cleave target 
DNA (or in some cases, RNA) (Horvath and Barrangou, 2010; Sorek et al., 2013; Barrangou 
and Marraffini, 2014). The adaptation stage is mediated by the complex of the Cas1 and 
Cas2 proteins, which are shared by all known CRISPR-Cas systems, and sometimes 
involves additional Cas proteins. Diversity is observed at the level of processing of the pre-
crRNA to mature crRNA guides, proceeding via either a Cas6-related ribonuclease or a 
housekeeping RNaseIII that specifically cleaves double stranded RNA hybrids of pre-
crRNA and tracrRNA. Moreover, the effector modules differ substantially among the 
CRISPR-Cas systems (Makarova et al., 2011; Makarova et al., 2015; Charpentier et al., 
2015). In the latest classification, the diverse CRISPR-Cas systems are divided into two 
classes according to the configuration of their effector modules: Class 1 CRISPR systems 
utilize several Cas proteins and the crRNA to form an effector complex, whereas Class 2 
CRISPR systems employ a large single-component Cas protein in conjunction with crRNAs 
to mediate interference (Makarova et al., 2015).
Zetsche et al. Page 2













Multiple Class 1 CRISPR-Cas systems, which include the type I and type III systems, have 
been identified and functionally characterized in detail, revealing the complex architecture 
and dynamics of the effector complexes (Brouns et al., 2008; Marraffini and Sontheimer, 
2008; Hale et al., 2009; Sinkunas et al., 2013; Jackson et al., 2014; Mulepati et al., 2014). 
Several Class 2 CRISPR-Cas systems have also been identified and experimentally 
characterized, but they are all type II and employ homologous RNA-guided endonucleases 
of the Cas9 family as effectors (Barrangou et al., 2007; Garneau et al., 2010; Deltcheva et 
al., 2011; Sapranauskas et al., 2011; Jinek et al., 2012; Gasiunas et al., 2012). A second, 
putative Class 2 CRISPR system, tentatively assigned to type V, has been recently identified 
in several bacterial genomes (http://www.jcvi.org/cgi-bin/tigrfams/HmmReportPage.cgi?
acc=TIGR04330) (Schunder et al., 2013; Vestergaard et al., 2014; Makarova et al., 2015). 
The putative type V CRISPR-Cas systems contain a large, ~1,300 amino acid protein called 
Cpf1 (CRISPR from Prevotella and Francisella 1). It remains unknown, however, if Cpf1-
containing CRISPR loci indeed represent functional CRISPR systems. Given the broad 
applications of Cas9 as a genome engineering tool (Hsu et al., 2014; Jiang and Marraffini, 
2015), we sought to explore the function of Cpf1-based putative CRISPR systems.
Here we show that Cpf1-containing CRISPR-Cas loci of Francisella tularensis subsp. 
novicida U112 encode functional defense systems capable of mediating plasmid interference 
in bacterial cells guided by the CRISPR spacers. Unlike Cas9 systems, Cpf1-containing 
CRISPR systems have three features: First, Cpf1-associated CRISPR arrays are processed 
into mature crRNAs without the requirement of an additional trans-activating crRNA 
(tracrRNA) (Deltcheva et al., 2011; Chylinski et al., 2013). Second, Cpf1-crRNA complexes 
efficiently cleave target DNA proceeded by a short T-rich protospacer adjacent motif 
(PAM), in contrast to the G-rich PAM following the target DNA for Cas9 systems. Third, 
Cpf1 introduces a staggered DNA double stranded break with a 4 or 5-nt 5′ overhang.
To explore the suitability of Cpf1 for genome editing applications, we characterized the 
RNA-guided DNA targeting requirements for 16 Cpf1-family proteins from diverse bacteria, 
we identify two Cpf1 enzymes, from Acidaminococcus sp. BV3L6 and Lachnospiraceae 
bacterium ND2006, that are capable of mediating robust genome editing in human cells. 
Collectively, these results establish a Class 2 CRISPR-Cas system that includes an effective 
single RNA-guided endonuclease with distinct properties that has the potential to 
substantially advance our ability to manipulate eukaryotic genomes.
RESULTS
Cpf1-containing CRISPR loci are active bacterial immune systems
Cpf1 was first annotated as a CRISPR-associated gene in TIGRFAM (http://www.jcvi.org/
cgi-bin/tigrfams/HmmReportPage.cgi?acc=TIGR04330) and has been hypothesized to be 
the effector of a CRISPR locus that is distinct from the Cas9-containing type II CRISPR-Cas 
loci that are also present in the genomes of some of the same bacteria, such as multiple 
strains of Francisella and Prevotella (Schunder et al., 2013; Vestergaard et al., 2014; 
Makarova et al., 2015) (Figure 1A). The Cpf1 protein contains a predicted RuvC-like 
endonuclease domain that is distantly related to the respective nuclease domain of Cas9. 
However, Cpf1 differs from Cas9 in that it lacks a second, HNH endonuclease domain, 
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which is inserted within the RuvC-like domain of Cas9. Furthermore, the N-terminal portion 
of Cpf1 is predicted to adopt a mixed α/β structure and appears to be unrelated to the N-
terminal, α-helical recognition lobe of Cas9 (Figure 1A). It has been shown that the nuclease 
moieties of Cas9 and Cpf1 are homologous to distinct groups of transposon-encoded TnpB 
proteins, the first one containing both RuvC and HNH nuclease domains and the second one 
containing the RuvC-like domain only (Makarova and Koonin, 2015). Apart from these 
distinctions between the effector proteins, the Cpf1-carrying loci encode Cas1, Cas2, and 
Cas4 proteins that are more closely related to orthologs from types I and III than to those 
from type II CRISPR systems (Makarova et al., 2015). Taken together, these differences 
from type II have prompted the classification of Cpf1-encoding CRISPR-Cas loci as the 
putative type V within Class 2 (Makarova et al., 2015). The features of the putative type V 
loci, especially the domain architecture of Cpf1, suggest not only that type II and type V 
systems independently evolved through the association of different adaptation modules 
(cas1, cas2, and cas4 genes) with different TnpB genes, but also that type V systems are 
functionally unique. The notion that Cpf1-carrying loci are bona fide CRISPR systems is 
further buttressed by the search of microbial genome sequences for similarity to the type V 
spacers which produced several significant hits to prophage genes, in particular those from 
Francisella (Schunder et al., 2013). Given these observations and the prevalence of Cpf1-
family proteins in diverse bacterial species, we sought to test the hypothesis that Cpf1-
encoding CRISPR-Cas loci are biologically active and can mediate targeted DNA 
interference, one of the primary functions of CRISPR systems.
To simplify experimentation, we cloned the Francisella tularensis subsp. novicida U112 
Cpf1 (FnCpf1) locus (Figure 1A) into low-copy plasmids (pFnCpf1) to allow heterologous 
reconstitution in Escherichia coli. Typically, in currently characterized CRISPR-Cas 
systems, there are two requirements for DNA interference: (i) the target sequence has to 
match one of the spacers present in the respective CRISPR array, and (ii) the target sequence 
complementary to the spacer (hereinafter protospacer) has to be flanked by the appropriate 
protospacer adjacent motif (PAM). Given the completely uncharacterized functionality of 
the FnCpf1 CRISPR locus, we adapted a previously described plasmid depletion assay 
(Jiang et al., 2013) to ascertain the activity of Cpf1 and identify the requirement for a PAM 
sequence and its respective location relative to the protospacer (5′ or 3′) (Figure 1B). We 
constructed two libraries of plasmids carrying a protospacer matching the first spacer in the 
FnCpf1 CRISPR array with the 5′ or 3′ 7 bp sequences randomized. Each plasmid library 
was transformed into E. coli that heterologously expressed the FnCpf1 locus or into a 
control E. coli strain carrying the empty vector. Using this assay, we determined the PAM 
sequence and location by identifying nucleotide motifs that are preferentially depleted in 
cells heterologously expressing the FnCpf1 locus. We found that the PAM for FnCpf1 is 
located upstream of the 5′ end of the displaced strand of the protospacer and has the 
sequence 5′-TTN (Figures 1C–D and S1). The 5′ location of the PAM is also observed in 
type I CRISPR systems, but not in type II systems, where Cas9 employs PAM sequences 
that are located on the 3′ end of the protospacer (Mojica et al., 2009; Garneau et al., 2010). 
Beyond the identification of the PAM, the results of the depletion assay clearly indicate that 
heterologously expressed Cpf1 loci are capable of efficient interference with plasmid DNA.
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To further characterize the PAM requirements, we analyzed plasmid interference activity by 
transforming cpf1-locus expressing cells with plasmids carrying protospacer 1 flanked by 5′-
TTN PAMs. We found that all 5′-TTN PAMs were efficiently targeted (Figure 1E). In 
addition, 5′-CTA but not 5′-TCA was also efficiently targeted (Figure 1E), suggesting that 
the middle T is more critical for PAM recognition than the first T and that, in agreement 
with the sequence motifs depleted in the PAM discovery assay (Figure S1D), the PAM 
might be more relaxed than 5′-TTN.
The Cpf1-associated CRISPR array is processed independent of tracrRNA
After showing that cpf1-based CRISPR loci are able to mediate robust DNA interference, 
we performed small RNA sequencing to determine the exact identity of the crRNA produced 
by these loci. By sequencing small RNAs extracted from a Francisella tularensis subsp. 
novicida U112 culture, we found that the CRISPR array is processed into short mature 
crRNAs of 42–44 nt in length. Each mature crRNA begins with 19 nt of the direct repeat 
followed by 23–25 nt of the spacer sequence (Figure 2A). This crRNA arrangement 
contrasts that in type II CRISPR-Cas systems where the mature crRNA starts with 20–24 nt 
of spacer sequence followed by ~22 nt of direct repeat (Deltcheva et al., 2011; Chylinski et 
al., 2013). Unexpectedly, apart from the crRNAs, we did not observe any robustly expressed 
small transcripts near the Francisella cpf1 locus that might correspond to tracrRNAs, which 
are associated with Cas9-based systems.
To confirm that no additional RNAs are required for crRNA maturation and DNA 
interference, we constructed an expression plasmid using synthetic promoters to drive the 
expression of Francisella cpf1 (FnCpf1) and the CRISPR array (pFnCpf1_min). Small 
RNAseq of E. coli expressing this plasmid still showed robust processing of the CRISPR 
array into mature crRNA (Figure 2B), indicating that FnCpf1 and its CRISPR array are the 
only elements required from the FnCpf1 locus to achieve crRNA processing. Furthermore, 
E. coli expressing pFnCpf1_min as well as pFnCpf1_ΔCas, a plasmid with all of the cas 
genes removed but retaining native promoters driving the expression of FnCpf1 and the 
CRISPR array, also exhibited robust DNA interference, demonstrating that FnCpf1 and 
crRNA are sufficient for mediating DNA targeting (Figure 2C). By contrast, Cas9 requires 
both crRNA and tracrRNA to mediate targeted DNA interference (Deltcheva et al., 2011; 
Zhang et al., 2013).
Cpf1 is a single crRNA-guided endonuclease
The finding that FnCpf1 can mediate DNA interference with crRNA alone is highly 
surprising given that Cas9 recognizes crRNA through the duplex structure between crRNA 
and tracrRNA (Jinek et al., 2012; Nishimasu et al., 2014), as well as the 3′ secondary 
structure of the tracrRNA (Hsu et al., 2013; Nishimasu et al., 2014). To ensure that crRNA 
is indeed sufficient for forming an active complex with FnCpf1 and mediating RNA-guided 
DNA cleavage, we investigated whether FnCpf1 supplied only with crRNA can cleave 
target DNA in vitro. We purified FnCpf1 (Figure S2) and assayed its ability to cleave the 
same protospacer 1-containing plasmid used in the bacterial DNA interference experiments 
(Figure 3A). We found that FnCpf1 along with an in vitro transcribed mature crRNA 
targeting protospacer 1 was able to efficiently cleave the target plasmid in a Mg2+- and 
Zetsche et al. Page 5













crRNA-dependent manner (Figure 3B). Moreover, FnCpf1 was able to cleave both 
supercoiled and linear target DNA (Figure 3C). These results clearly demonstrate the 
sufficiency of FnCpf1 and crRNA for RNA-guided DNA cleavage.
We also mapped the cleavage site of FnCpf1 using Sanger sequencing of the cleaved DNA 
ends. We found that FnCpf1-mediated cleavage results in a 5-nt 5′ overhang (Figures 3A, 
3D, and S3A–D), which is different from the blunt cleavage product generated by Cas9 
(Garneau et al., 2010; Jinek et al., 2012; Gasiunas et al., 2012). The staggered cleavage site 
of FnCpf1 is distant from the PAM: cleavage occurs after the 18th base on the non-targeted 
(+) strand and after the 23rd base on the targeted (−) strand (Figures 3A, 3D, and S3A–D). 
Using double-stranded oligo substrates with different PAM sequences, we also found that 
FnCpf1 requires the 5′-TTN PAM to be in a duplex form in order to cleave the target DNA 
(Figure 3E).
The RuvC-like domain of Cpf1 mediates RNA-guided DNA cleavage
The RuvC-like domain of Cpf1 retains all the catalytic residues of this family of 
endonucleases (Figures 4A and S4) and is thus predicted to be an active nuclease. Therefore 
we generated three mutants, FnCpf1(D917A), FnCpf1(E1006A), and FnCpf1(D1225A) 
(Figure 4A) to test whether the conserved catalytic residues are essential for the nuclease 
activity of FnCpf1. We found that the D917A and E1006A mutations completely inactivated 
the DNA cleavage activity of FnCpf1, and D1255A significantly reduced nucleolytic 
activity (Figure 4B). These results are in contrast to the mutagenesis results for 
Streptococcus pyogenes Cas9 (SpCas9), where mutation of the RuvC (D10A) and HNH 
(N863A) nuclease domains converts SpCas9 into a DNA nickase (i.e. inactivation of each of 
the two nuclease domains abolished the cleavage of one of the DNA strands) (Jinek et al., 
2012; Gasiunas et al., 2012) (Figure 4B). These findings suggest that the RuvC-like domain 
of FnCpf1 cleaves both strands of the target DNA, perhaps in a dimeric configuration. 
Interestingly, size exclusion gel filtration of FnCpf1 shows that the protein is eluted at a size 
of approximately 300 kD, twice the molecular weight of a FnCpf1 monomer (Figure S2B).
Sequence and structural requirements for the Cpf1 crRNA
Compared with the guide RNA for Cas9, which has elaborate RNA secondary structure 
features that interact with Cas9 (Nishimasu et al., 2014), the guide RNA for FnCpf1 is 
notably simpler and only consists of a single stem loop in the direct repeat sequence (Figure 
3A). We explored the sequence and structural requirements of crRNA for mediating DNA 
cleavage with FnCpf1.
We first examined the length requirement for the guide sequence and found that FnCpf1 
requires at least 16 nt of guide sequence to achieve detectable DNA cleavage and a 
minimum of 18 nt of guide sequence to achieve efficient DNA cleavage in vitro (Figure 
5A). These requirements are similar to those demonstrated for SpCas9 where a minimum of 
16 to 17 nt of spacer sequence is required for DNA cleavage (Cencic et al., 2014; Fu et al., 
2014). We also found that the seed region of the FnCpf1 guide RNA is approximately within 
the first 5 nt on the 5′ end of the spacer sequence (Figures 5B and S3E).
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Next, we studied the effect of direct repeat mutations on the RNA-guided DNA cleavage 
activity. The direct repeat portion of mature crRNA is 19 nt long (Figure 2A). Truncation of 
the direct repeat revealed that at least 16, but optimally more than 17 nt, of the direct repeat 
is required for cleavage. Mutations in the stem loop that preserved the RNA duplex did not 
affect the cleavage activity, whereas mutations that disrupted the stem loop duplex structure 
completely abolished cleavage (Figure 5D). Finally, base substitutions in the loop region did 
not affect nuclease activity, whereas the U immediately 5′ of the spacer sequence could not 
be substituted (Figure 5E). Collectively, these results suggest that FnCpf1 recognizes the 
crRNA through a combination of sequence-specific and structural features of the stem loop.
Cpf1-family proteins from diverse bacteria share common crRNA structures and PAMs
Based on our previous experience in harnessing Cas9 for genome editing in mammalian 
cells, only a small fraction of bacterial nucleases can function efficiently when 
heterologously expressed in mammalian cells (Cong et al., 2013; Ran et al., 2015). 
Therefore, in order to assess the feasibility of harnessing Cpf1 as a genome editing tool, we 
exploited the diversity of Cpf1-family proteins available in the public sequences databases. 
A BLAST search of the WGS database at the NCBI revealed 46 non-redundant Cpf1-family 
proteins (Figure S5A), from which we chose 16 candidates that, based on our phylogenetic 
reconstruction (Figure S5A), represented the entire Cpf1 diversity (Figures 6A and S5). 
These Cpf1-family proteins span a range of lengths between ~1200 and ~1500 amino acids.
The direct repeat sequences for each of these Cpf1-family proteins show strong conservation 
in the 19 nucleotides at the 3′ of the direct repeat, the portion of the repeat that is included in 
the processed crRNA (Figure 6B). The 5′ sequence of the direct repeat is much more 
diverse. Of the 16 Cpf1-family proteins chosen for analysis, three (2 - Lachnospiraceae 
bacterium MC2017, Lb3Cpf1; 3 - Butyrivibrio proteoclasticus, BpCpf1; and 6 - Smithella 
sp. SC_K08D17, SsCpf1) were associated with direct repeat sequences that are notably 
divergent from the FnCpf1 direct repeat (Figure 6B). However, even these direct repeat 
sequences preserved stem loop structures that were identical or nearly-identical to the 
FnCpf1 direct repeat (Figure 6C).
Given the strong structural conservation of the direct repeats that are associated with many 
of the Cpf1-family proteins, we first tested whether the orthologous direct repeat sequences 
are able to support FnCpf1 nuclease activity in vitro. As expected, the direct repeats that 
contained conserved stem sequences were able to function interchangeably with FnCpf1. By 
contrast, the direct repeats from candidate 2 (Lb3Cpf1) and 6 (SsCpf1) were unable to 
support FnCpf1 cleavage activity (Figure 6D). The direct repeat from candidate 3 (BpCpf1) 
supported only a low level of FnCpf1 nuclease activity (Figure 6D), possibly due to the 
conservation of the 3′-most U.
Next, we applied the in vitro PAM identification assay (Figure S6A) to determine the PAM 
sequence for each Cpf1-family protein. We were able to identify the PAM sequence for 7 
new Cpf1-family proteins (Figures 6E and S6B–C), and the screen confirmed the PAM for 
FnCpf1 as 5′-TTN. The remaining 8 tested Cpf1 proteins did not show efficient cleavage 
during in vitro reconstitution. The PAM sequences for the Cpf1-family proteins were 
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predominantly T-rich, only varying in the number of Ts constituting each PAM (Figure 6E 
and S6B–C).
Cpf1 can be harnessed to facilitate genome editing in human cells
We tested each Cpf1-family protein, for which we were able to identify a PAM, for nuclease 
activity in mammalian cells. We codon optimized each of these genes and attached a C-
terminal nuclear localization signal (NLS) for optimal expression and nuclear targeting in 
human cells (Figure 7A). To test the activity of each Cpf1-family protein, we selected a 
guide RNA target site within the DNMT1 gene (Figure 7B). We first found that each of the 
Cpf1-family proteins along with its respective crRNA designed to target DNMT1 was able to 
cleave a PCR amplicon of the DNMT1 genomic region in vitro (Figure 7C). However, when 
tested in human embryonic kidney 293FT (HEK 293FT) cells, only 2 out of the 8 Cpf1-
family proteins (7 – AsCpf1 and 13 – LbCpf1) exhibited detectable levels of nuclease-
induced indels (Figures 7C and 7D). This result is consistent with previous experiments with 
Cas9 where only a small number of Cas9 orthologs were successfully harnessed for genome 
editing in mammalian cells (Ran et al., 2015).
We further tested each Cpf1-family protein with additional genomic targets and found that 
AsCpf1 and LbCpf1 consistently mediated robust genome editing in HEK293FT cells, 
whereas the remaining Cpf1 proteins showed either no detectable activity or only sporadic 
activity (Figures 7E and S7), despite robust expression (Figure S6D). The only Cpf1 
candidate that expressed poorly was PdCpf1 (Figure S6D). When compared to Cas9, 
AsCpf1 and LbCpf1 mediated comparable levels of indel formation (Figure 7E). 
Additionally, we used in vitro cleavage followed by Sanger sequencing of the cleaved DNA 
ends and found that 7 - AsCpf1 and 13 - LbCpf1 also generated staggered cleavage sites 
(Figures S6E and S6F, respectively).
DISCUSSION
In this work, we characterize Cpf1-containing Class 2 CRISPR systems, classified as type 
V, and show that its effector protein, Cpf1, is a single RNA-guided endonuclease. Cpf1 
substantially differs from Cas9, to date the only other experimentally characterized Class 2 
effector, in terms of structure and function and might provide important advantages for 
genome editing applications. Specifically, Cpf1 contains a single identified nuclease 
domain, in contrast to the two nuclease domains present in Cas9. The results presented here 
show that in FnCpf1, inactivation of RuvC-like domain abolishes cleavage of both DNA 
strands. Conceivably, FnCpf1 forms a homodimer (Figure S2B), with the RuvC-like 
domains of each of the two subunits cleaving one DNA strand. However, it is also likely that 
FnCpf1 contains a second yet-to-be-identified nuclease domain. Structural characterization 
of Cpf1-RNA-DNA complexes will allow testing of these hypotheses and elucidating the 
cleavage mechanism.
Perhaps the most notable feature of Cpf1 is that it is a single crRNA-guided endonuclease. 
Unlike Cas9, which requires tracrRNA to process crRNA arrays and both crRNA and 
tracrRNA to mediate interference (Deltcheva et al., 2011), Cpf1 processes crRNA arrays 
independent of tracrRNA and Cpf1-crRNA complexes alone cleave target DNA molecules, 
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without the requirement for any additional RNA species. This feature could simplify the 
design and delivery of genome editing tools. For example, the shorter (~42 nt) crRNA 
employed by Cpf1 has practical advantages over the long (~100 nt) guide RNA in Cas9-
based systems, because shorter RNA oligos are significantly easier and cheaper to 
synthesize. In addition, these findings raise more fundamental questions regarding the guide 
processing mechanism of the type V CRISPR-Cas systems. In the case of type II, processing 
of the pre-crRNA is catalyzed by the bacterial RNAse III, which recognizes the long duplex 
formed by the tracrRNA and the complementary portion of the direct repeat (Deltcheva et 
al., 2011). Such long duplexes are not present in the pre-crRNA of type V systems, making 
it unlikely that RNAse III is responsible for processing. Further experiments aimed at 
elucidating the processing mechanism of type V systems will shed light on the functional 
diversity of different CRISPR-Cas systems.
Cpf1 generates a staggered cut with a 5′ overhang, in contrast to the blunt ends generated by 
Cas9 (Garneau et al., 2010; Jinek et al., 2012; Gasiunas et al., 2012). This structure of the 
cleavage product could be particularly advantageous for facilitating non-homologous end 
joining (NHEJ)-based gene insertion into the mammalian genome (Maresca et al., 2013). 
Being able to program the exact sequence of a sticky end would allow researchers to design 
the DNA insert so that it integrates into the genome in the proper orientation. Specifically, in 
non-dividing cells, where genome editing via homology-directed repair (HDR) mechanisms 
are especially challenging (Chan et al., 2011), Cpf1 could provide an effective way to 
precisely introduce DNA into the genome via non-HDR mechanisms.
Another potentially useful feature of Cpf1 that might aid the introduction of new DNA 
sequences is that Cpf1 cleaves target DNA at the distal end of the protospacer, far away 
from the seed region. Therefore, Cpf1-induced indels will be located far from the target site, 
which is thus preserved for subsequent rounds of Cpf1 cleavage. With Cas9, any indel 
resulting from the dominant NHEJ repair pathway will disrupt the target site, effectively 
eliminating the possibility of inserting new DNA at that site in that particular cell. In the 
case of Cpf1, it appears possible that, if the first round of targeting results in an indel, a 
subsequent round of targeting could yet be repaired via HDR. Future exploration of these 
and other strategies using Cpf1 and other Class 2 effectors is expected to bring solutions for 
some of the biggest challenges facing genome editing.
The T-rich PAMs of the Cpf1 family also allow for applications in genome editing in 
organisms with particularly AT-rich genomes, such as Plasmodium falciparum (Gardner et 
al., 2002), or areas of interest with AT-enrichment, such as scaffold/matrix attachment 
regions. To date, all characterized mammalian genome editing proteins require the presence 
of at least one G (Hsu et al., 2014; Jiang et al., 2015), so the T and T/C-dependent PAMs of 
Cpf1-family proteins expand the targeting range of RNA-guided genome editing nucleases.
The natural diversity of CRISPR systems provides a wealth of opportunities for 
understanding the origin and evolution of prokaryotic adaptive immunity, as well as for 
harnessing potentially transformative biotechnological tools. There is little doubt that, 
beyond the already classified and characterized diversity of the CRISPR-Cas types, there are 
additional systems with distinctive characteristics that await exploration and could further 
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enhance genome editing and other areas of biotechnology as well as shed further light on the 
evolution of these defense systems.
EXPERIMENTAL PROCEDURES
Generation of heterologous plasmids
To generate the FnCpf1 locus for heterologous expression, genomic DNA from Francisella 
Novicida (generous gift from Wayne Conlan) was PCR amplified using Herculase II 
polymerase (Agilent Technologies) and cloned into pACYC-184 using Gibson cloning 
(New England Biolabs). Cells harboring plasmids were made competent using the Z-
competent kit (Zymo). Sequences of all bacterial expression plasmids can be found in Table 
S1.
Bacterial RNA-sequencing
RNA was isolated from stationary phase bacteria by first resuspending F. novicida 
(generous gift from David Weiss) or E. coli in TRIzol and then homogenizing the bacteria 
with zirconia/silica beads (BioSpec Products) in a BeadBeater (BioSpec Products) for 3 one-
minute cycles. Total RNA was purified from homogenized samples with the Direct-Zol 
RNA miniprep protocol (Zymo), DNase treated with TURBO DNase (Life Technologies), 
and 3′ dephosphorylated with T4 Polynucleotide Kinase (New England Biolabs). rRNA was 
removed with the bacterial Ribo-Zero rRNA removal kit (Illumina). RNA libraries were 
prepared from rRNA-depleted RNA using NEBNext® Small RNA Library Prep Set for 
Illumina (New England Biolabs) and size selected using the Pippin Prep (Sage Science)
For heterologous E. coli expression of the FnCpf1 locus, RNA sequencing libraries were 
prepared from rRNA-depleted RNA using a derivative of the previously described CRISPR 
RNA sequencing method (Heidrich et al., 2015). Briefly, transcripts were poly-A tailed with 
E. coli Poly(A) Polymerase (New England Biolabs), ligated with 5′ RNA adapters using T4 
RNA Ligase 1 (ssRNA Ligase) High Concentration (New England Biolabs), and reverse 
transcribed with AffinityScript Multiple Temperature Reverse Transcriptase (Agilent 
Technologies). cDNA was PCR amplified with barcoded primers using Herculase II 
polymerase (Agilent Technologies).
RNA-sequencing analysis
The prepared cDNA libraries were sequenced on a MiSeq (Illumina). Reads from each 
sample were identified on the basis of their associated barcode and aligned to the 
appropriate RefSeq reference genome using BWA (Li and Durbin, 2009). Paired-end 
alignments were used to extract entire transcript sequences using Picard tools (http://
broadinstitute.github.io/picard), and these sequences were analyzed using Geneious 8.1.5.
In vivo FnCpf1 PAM Screen
Randomized PAM plasmid libraries were constructed using synthesized oligonucleotides 
(IDT) consisting of 7 randomized nucleotides either upstream or downstream of the FnCpf1 
spacer 1. The randomized ssDNA oligos (Table S1) were made double stranded by 
annealing to a short primer and using the large Klenow fragment (New England Biolabs) for 
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second strand synthesis. The dsDNA product was assembled into a linearized pUC19 using 
Gibson cloning (New England Biolabs). Competent Stbl3 E. coli (Invitrogen) were 
transformed with the cloned products, and more than 107 cells were collected and pooled. 
Plasmid DNA was harvested using a Maxi-prep kit (Qiagen). We transformed 360 ng of the 
pooled library into E. coli cells carrying the FnCpf1 locus or pACYC184 control. After 
transformation, cells were plated on ampicillin. After 16 hours of growth, >4*106 cells were 
harvested and plasmid DNA was extracted using a Maxi-prep kit (Qiagen). The target PAM 
region was amplified and sequenced using a MiSeq (Illumina) with single-end 150 cycles.
Computational PAM discovery pipeline
PAM regions were extracted, counted, and normalized to total reads for each sample. For a 
given PAM, enrichment was measured as the log ratio compared to pACYC184 control, 
with a 0.01 psuedocount adjustment. PAMs above a 3.5 enrichment threshold were collected 
and used to generate sequence logos (Crooks et al., 2004).
PAM validation
Sequences corresponding to both PAMs non-PAMs were cloned into digested pUC19 and 
ligated with T4 ligase (Enzymatics). Competent E. coli with either the FnCpf1 locus plasmid 
or pACYC184 control plasmid were transformed with 20ng of PAM plasmid and plated on 
LB agar plates supplemented with ampicillin and chloramphenicol. Colonies were counted 
after 18 hours.
Synthesis of crRNAs and sgRNAs
All crRNA and sgRNAs used in vitro were synthesized using the HiScribe™ T7 High Yield 
RNA Synthesis Kit (NEB). ssDNA oligos (Table S1) corresponding to the reverse 
complement of the target RNA sequence were synthesized from IDT and annealed to a short 
T7 priming sequence. T7 transcription was performed for 4 hours and then RNA was 
purified using the MEGAclear™ Transcription Clean-Up Kit (Ambion).
Purification of Cpf1 Protein
FnCpf1 protein was cloned into a bacterial expression vector (6-His-MBP-TEV-Cpf1, a pET 
based vector kindly given to us by Doug Daniels). Two liters of Terrific Broth growth media 
with 100 μg/mL ampicillin was inoculated with 10 mL overnight culture Rosetta (DE3) 
pLyseS (EMD Millipore) cells containing the Cpf1 expression construct. Growth media plus 
inoculant was grown at 37 °C until the cell density reached 0.2 OD600, then the temperature 
was decreased to 21°C. Growth was continued until OD600 reached 0.6 when a final 
concentration of 500 μM IPTG was added to induce MBP-Cpf1 expression. The culture was 
induced for 14–18 hours before harvesting cells and freezing at −80°C until purification.
Cell paste was resuspended in 200 mL of Lysis Buffer (50 mM Hepes pH 7, 2M NaCl, 5 
mM MgCl2, 20 mM imidazole) supplemented with protease inhibitors (Roche cOmplete, 
EDTA-free) and lysozyme. Once homogenized, cells were lysed by sonication (Branson 
Sonifier 450) then centrifuged at 10,000g for 1 hour to clear the lysate. The lysate was 
filtered through 0.22 micron filters (Millipore, Stericup) and applied to a nickel column 
(HisTrap FF, 5 mL), washed, and then eluted with a gradient of imidazole. Fractions 
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containing protein of the expected size were pooled, TEV protease (Sigma) was added, and 
the sample was dialyzed overnight into TEV buffer (500 mM NaCl, 50 mM Hepes pH 7, 5 
mM MgCl, 2 mM DTT). After dialysis, TEV cleavage was confirmed by SDS-PAGE, and 
the sample was concentrated to 500 μL prior to loading on a gel filtration column (HiLoad 
16/600 Superdex 200) via FPLC (AKTA Pure). Fractions from gel filtration were analyzed 
by SDS-PAGE; fractions containing Cpf1 were pooled and concentrated to 200 μL and 
either used directly for biochemical assays or frozen at −80°C for storage. Gel filtration 
standards were run on the same column equilibrated in 2M NaCl, Hepes pH 7.0 to calculate 
the approximate size of FnCpf1.
Generation of Cpf1 Protein Lysate
Cpf1 proteins codon optimized for human expression were synthesized with an N-terminal 
nuclear localization tag and cloned into the pcDNA3.1 expression plasmid by Genscript. 
2000ng of Cpf1 expression plasmids were transfected into 6-well plates of HEK293FT cells 
at 90% confluency using Lipofectamine 2000 reagent (Life Technologies). 48 hours later, 
cells were harvested by washing once with DPBS (Life Technologies) and scraping in lysis 
buffer [20mM Hepes pH 7.5, 100mM KCl, 5mM MgCl2, 1 mM DTT, 5% glycerol, 0.1% 
Triton X-100, 1X cOmplete Protease Inhibitor Cocktail Tablets (Roche)]. Lysate was 
sonicated for 10 minutes in a Biorupter sonicator (Diagenode) and then centrifuged. 
Supernatant was frozen for subsequent use in in vitro cleavage assays.
In vitro cleavage assay
Cleavage in vitro was performed either with purified protein or mammalian lysate with 
protein at 37°C in cleavage buffer (NEBuffer 3, 5mM DTT) for 20 minutes. The cleavage 
reaction used 500ng of synthesized crRNA or sgRNA and 200ng of target DNA. Target 
DNA involved either protospacers cloned into pUC19 or PCR amplicons of gene regions 
from genomic DNA isolated from HEK293 cells. Reactions were cleaned up using PCR 
purification columns (Qiagen) and run on 2% agarose E-gels (Life Technologies). For native 
and denaturing gels to analyze cleavage by nuclease mutants, cleaned-up reactions were run 
on TBE 6% polyacrylamide or TBE-Urea 6% polyacrylamide gels (Life Technologies)
In vitro Cpf1-family protein PAM Screen
In vitro cleavage reactions with Cpf1-family proteins were run on 2% agarose E-gels (Life 
Technologies). Bands corresponding to un-cleaved target were gel extracted using QIAquick 
Gel Extraction Kit (Qiagen) and the target PAM region was amplified and sequenced using 
a MiSeq (Illumina) with single-end 150 cycles. Sequencing results were entered into the 
PAM discovery pipeline.
Western blot analysis
Cells were lysed in 1xRIPA buffer (Cell Signaling Technology) supplemented with protease 
inhibitor cocktail (Roche). Equal volumes cell lysate were run on BOLT 4–12% Bis-Tris 
gradient gels (Invitrogen) and transferred to PVDF membranes (Millipore). Non-specific 
antigen binding was blocked with TBS-T (50mM Tris, 150mM NaCl and 0.05% Tween-20) 
with 5% BLOT-QuickBlocker Reagent (Millipore) for 1 hour. Membranes were incubated 
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with primary antibodies (anti-HA-tag (Cell Signaling Technology C29F4) or HRP-
conjugated GAPDH (Cell Signaling Technology 14C10)) for 1 hour in 1% BLOT-
QuickBlocker. Membranes were washed for 3 10 minute washes and anti-HA-tag 
membranes were further incubated with anti-rabbit antibody (Cell Signaling Technology 
7074) for 1h followed by 6 10 minute washes in TBS-T. Proteins were visualized with West 
Pico Chemiluminescent Substrate (Life Technology) and imaged using the ChemiDoc MP 
Imaging System (Bio-Rad) and processed with ImageLab software (Bio-Rad).
Activity of Cpf1 cleavage in 293FT cells
Cpf1 proteins codon optimized for human expression were synthesized with an N-terminal 
nuclear localization tag and cloned into the pcDNA3.1 CMV expression plasmid by 
Genscript (Table S1). PCR amplicons comprised of a U6 promoter driving expression of the 
crRNA sequence were generated using Herculase II (Agilent Technologies) and appropriate 
U6 reverse primers (Table S2). 400ng of Cpf1 expression plasmids and 100ng of the crRNA 
PCR products were transfected into 24-well plates of HEK293FT cells at 75–90% 
confluency using Lipofectamine 2000 reagent (Life Technologies). Genomic DNA was 
harvested using QuickExtract™ DNA Extraction Solution (Epicentre).
SURVEYOR nuclease assay for genome modification
293FT cells were transfected with 400ng Cpf1 expression plasmid and 100ng U6::crRNA 
PCR-fragments using Lipofectamin 2000 reagent (Life Technologies). Cells were incubated 
at 37 °C for 72 h post-transfection before genomic DNA extraction. Genomic DNA was 
extracted using the QuickExtract DNA Extraction Solution (Epicentre) following the 
manufacturer’s protocol. The genomic region flanking the CRISPR target site for each gene 
was PCR amplified, and products were purified using QiaQuick Spin Column (Qiagen) 
following the manufacturer’s protocol. 200 – 500 ng total of the purified PCR products were 
mixed with 1 μl 10× Taq DNA Polymerase PCR buffer (Enzymatics) and ultrapure water to 
a final volume of 10 μl, and subjected to a re-annealing process to enable heteroduplex 
formation: 95 °C for 10 min, 95 °C to 85 °C ramping at −2 °C/s, 85 °C to 25 °C at −0.25 
°C/s, and 25 °C hold for 1 min. After re-annealing, products were treated with SURVEYOR 
nuclease and SURVEYOR enhancer S (Integrated DNA Technologies) following the 
manufacturer’s recommended protocol, and analyzed on 4–20% Novex TBE polyacrylamide 
gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life 
Technologies) for 10 min and imaged with a Gel Doc gel imaging system (Bio-rad). 
Quantification was based on relative band intensities. Indel percentage was determined by 
the formula, 100 × (1 − (1 − (b + c)/(a + b + c))1/2), where a is the integrated intensity of the 
undigested PCR product, and b and c are the integrated intensities of each cleavage product.
Deep sequencing to characterize Cpf1 indel patterns in 293FT cells
HEK293FT cells were transfected and harvested as described for assessing activity of Cpf1 
cleavage. The genomic region flanking DNMT1 targets were amplified using a two-round 
PCR region to add Illumina P5 adapters as well as unique sample-specific barcodes to the 
target amplicons. PCR products were ran on 2% E-gel (Invitrogen) and gel-extracted using 
QiaQuick Spin Column (Qiagen) as per the manufacturer’s recommended protocol. Samples 
were pooled and quantified by Qubit 2.0 Fluorometer (Life Technologies). The prepared 
Zetsche et al. Page 13













cDNA libraries were sequenced on a MiSeq (Illumina). Indels were mapped using a Python 
implementation of the Geneious 6.0.3 Read Mapper.
Computational Analysis of Cpf1 loci
PSI-BLAST program (Altschul et al., 1997) was used to identify Cpf1 homologs in the 
NCBI NR database using several known Cpf1 sequences as queries with the Cpf1 with the 
E-value cutoff of 0.01 and low complexity filtering and composition based statistics turned 
off. The TBLASTN program with the E-value cut-off of 0.01 and low complexity filtering 
turned off parameters was used to search the NCBI WGS database using the Cpf1 profile 
(Makarova et al., 2015) as the query. Results of all searches were combined (Table S3). The 
HHpred program was used with default parameters (Soding et al., 2006) to identify remote 
sequence similarity using a subset of representative Cpf1 sequences queries. Multiple 
sequence alignment were constructed using MUSCLE (Edgar, 2004) with manual correction 
based on pairwise alignments obtained using PSI-BLAST and HHpred programs. 
Phylogenetic analysis was performed using the FastTree program with the WAG 
evolutionary model and the discrete gamma model with 20 rate categories (Price et al., 
2010). Protein secondary structure was predicted using Jpred 4 (Drozdetskiy et al., 2015). 
CRISPR repeats were identified using PILER-CR (Edgar, 2007) and CRISPRfinder (Grissa 
et al., 2007).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The Francisella tularensis subsp. novicida U112 Cpf1 CRISPR locus provides immunity 
against transformation of plasmids containing protospacers flanked by a 5′-TTN PAM
(A) Organization of two CRISPR loci found in Francisella tularensis subsp. novicida U112 
(NC_008601). The domain architectures of FnCas9 and FnCpf1 are compared.
(B) Schematic illustrating the plasmid depletion assay for discovering the PAM position and 
identity. Competent E. coli harboring either the heterologous FnCpf1 locus plasmid 
(pFnCpf1) or the empty vector control were transformed with a library of plasmids 
containing the matching protospacer flanked by randomized 5′ or 3′ PAM sequences and 
selected with antibiotic to deplete plasmids carrying successfully-targeted PAM. Plasmids 
from surviving colonies were extracted and sequenced to determine depleted PAM 
sequences.
(C) Sequence logo for the FnCpf1 PAM as determined by the plasmid depletion assay. 
Letter height at each position is measured by information content; error bars show 95% 
Bayesian confidence interval.
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(D) E. coli harboring pFnCpf1 provides robust interference against plasmids carrying 5′-
TTN PAMs (n = 3, error bars represent mean ± S.E.M.).
See also Figure S1.
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Figure 2. Heterologous expression of FnCpf1 and CRISPR array in E. coli is sufficient to 
mediate plasmid DNA interference and crRNA maturation
(A) Small RNA-seq of Francisella tularensis subsp. novicida U112 reveals transcription and 
processing of the FnCpf1 CRISPR array. The mature crRNA begins with a 19 nt partial 
direct repeat followed by 23–25 nt of spacer sequence.
(B) Small RNA-seq of E. coli transformed with a plasmid carrying synthetic promoter-
driven FnCpf1 and CRISPR array shows crRNA processing independent of Cas genes and 
other sequence elements in the FnCpf1 locus.
(C) E. coli harboring different truncations of the FnCpf1 CRISPR locus shows that only 
FnCpf1 and the CRISPR array are required for plasmid DNA interference (n = 3, error bars 
show mean ± S.E.M.).
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Figure 3. FnCpf1 is guided by crRNA to cleave DNA in vitro
(A) Schematic of the FnCpf1 crRNA-DNA targeting complex. Cleavage sites are indicated 
by red arrows.
(B) FnCpf1 and crRNA alone mediated RNA-guided cleavage of target DNA in a crRNA- 
and Mg2+-dependent manner.
(C) FnCpf1 cleaves both linear and supercoiled DNA.
(D) Sanger sequencing traces from FnCpf1-digested target show staggered overhangs. The 
non-templated addition of an additional adenine, denoted as N, is an artifact of the 
polymerase used in sequencing (Clark, 1988). Reverse primer read represented as reverse 
complement to aid visualization. See also Figure S3.
(E) Dependency of cleavage on base-pairing at the 5′ PAM. FnCpf1 can only recognize the 
PAM in correctly Watson-Crick paired DNA.
See also Figures S2 and S3.
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Figure 4. Catalytic residues in the C-terminal RuvC domain of FnCpf1 are required for DNA 
cleavage
(A) Domain structure of FnCpf1 with RuvC catalytic residues highlighted. The catalytic 
residues were identified based on sequence homology to Thermus thermophilus RuvC (PDB 
ID: 4EP5).
(B) Native TBE PAGE gel showing that mutation of the RuvC catalytic residues of FnCpf1 
(D917A and E1006A) and mutation of the RuvC (D10A) catalytic residue of SpCas9 
prevents double stranded DNA cleavage. Denaturing TBE-Urea PAGE gel showing that 
mutation of the RuvC catalytic residues of FnCpf1 (D917A and E1006A) prevents DNA 
nicking activity, whereas mutation of the RuvC (D10A) catalytic residue of SpCas9 results 
in nicking of the target site.
See also Figure S4.
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Figure 5. crRNA requirements for FnCpf1 nuclease activity in vitro
(A) Effect of spacer length on FnCpf1 cleavage activity.
(B) Effect of crRNA-target DNA mismatch on FnCpf1 cleavage activity. See also Figure 
S3E.
(C) Effect of direct repeat length on FnCpf1 cleavage activity.
(D) FnCpf1 cleavage activity depends on secondary structure in the stem of the direct repeat 
RNA structure.
(E) FnCpf1 cleavage activity is unaffected by loop mutations but is sensitive to mutation in 
the 3′-most base of the direct repeat.
See also Figure S4.
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Figure 6. Analysis of Cpf1-family protein diversity and function
(A) Phylogenetic tree of 16 Cpf1 orthologs selected for functional analysis. Conserved 
sequences are shown in dark gray. The RuvC domain, bridge helix, and zinc finger are 
highlighted.
(B) Alignment of direct repeats from the 16 Cpf1-family proteins. Sequences that are 
removed post crRNA maturation are colored gray. Non-conserved bases are colored red. 
The stem duplex is highlighted in gray.
(C) RNAfold (Lorenz et al., 2011) prediction of the direct repeat sequence in the mature 
crRNA. Predictions for FnCpf1 along with three diverged type V loci are shown.
(D) Type V crRNAs from different bacteria with similar direct repeat sequences are able to 
function with FnCpf1 to mediate target DNA cleavage.
(E) PAM sequences for 8 Cpf1-family proteins identified using in vitro cleavage of a 
plasmid library containing randomized PAMs flanking the protospacer.
See also Figures S5 and S6.
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Figure 7. Cpf1 mediates robust genome editing in human cell lines
(A) Eight Cpf1-family proteins are individually expressed in HEK 293FT cells using CMV-
driven expression vectors. The corresponding crRNA is expressed using a PCR fragment 
containing a U6 promoter fused to the crRNA sequence. Transfected cells were analyzed 
using either Surveyor nuclease assay or targeted deep sequencing.
(B) Schematic showing the sequence of DNMT1-targeting crRNA 3. Sequencing reads 
show representative indels.
(C) Comparison of in vitro and in vivo cleavage activity. The DNMT1 target region was 
PCR amplified and the genomic fragment was used to test Cpf1-mediated cleavage. All 8 
Cpf1-family proteins showed DNA cleavage in vitro (top), but only candidates 7 – AsCpf1 
and 13 – Lb3Cpf1 facilitated robust indel formation in human cells.
(D) Cpf1 and SpCas9 target sequences in the human DNMT1 locus.
(E) Comparison of Cpf1 and SpCas9 genome editing efficiency. Target sites correspond to 
sequences shown in Figure 7D.
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See also Figure S7.
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